Silencing of the Activated Protein-1 Transcription Factor JunD Exacerbates Ischemia/Reperfusion-induced Cerebral Injury

Similar documents
SUPPLEMENTARY INFORMATION

In the name of GOD. Animal models of cardiovascular diseases: myocardial infarction & hypertension

Stroke 101. Maine Cardiovascular Health Summit. Eileen Hawkins, RN, MSN, CNRN Pen Bay Stroke Program Coordinator November 7, 2013

Cerebrovascular Disorders. Blood, Brain, and Energy. Blood Supply to the Brain 2/14/11

The Impact of Smoking on Acute Ischemic Stroke

c Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p.

Nicolas Bianchi M.D. May 15th, 2012

Shawke A. Soueidan, MD. Riverside Neurology & Sleep Specialists

Watermark. Interaction between Neuropathy and PAD

Pathophysiology and treatment of focal cerebral ischemia

PFO Management update

WHITE PAPER: A GUIDE TO UNDERSTANDING SUBARACHNOID HEMORRHAGE

Imaging ischemic strokes: Correlating radiological findings with the pathophysiological evolution of an infarct

SAFETY AND EFFECTIVENESS OF ENDOVASCULAR REVASCULARIZATION FOR PERIPHERAL ARTERIAL OCCLUSIONS

Stroke Net Grand Round Webinar

CEREBRO VASCULAR ACCIDENTS

Gene expression was analyzed by real time PCR (SYBR GREEN PCR Master. Mix, Roche Applied Science) using specific oligonucleotides.

From interventional cardiology to cardio-neurology. A new subspeciality

Frequency of Cardiac Risk Factors in. Ischemic

Stroke, the most common medical emergency, is a

Ambulatory Care Conference

Sleep and the Heart. Sleep Stages. Sleep and the Heart: non REM 8/31/2016

BY: Ramon Medina EMT-LP/RN

How We Breathe During Sleep Affects Health, Wellness and Longevity

Neuropathology lecture series. III. Neuropathology of Cerebrovascular Disease. Physiology of cerebral blood flow

Reperfusion Injury: How Can We Reduce It?

Pathophysiology of stroke

Stroke Update. Claire J. Creutzfeldt, MD January 12, 2018

Unclogging The Pipes. Zahraa Rabeeah MD Chief Resident February 9,2018

11/2/2016. Stroke. Carl F. McComas, M.D. November 3, Disclosures. None (of any kind)

WHI Form Report of Cardiovascular Outcome Ver (For items 1-11, each question specifies mark one or mark all that apply.

Clinical application of Arterial stiffness. pulse wave analysis pulse wave velocity

Raluca Pavaloiu et al. - Clinical, Epidemiological and Etiopathogenic Study of Ischemic Stroke

Takotsubo Cardiomyopathy: Pathophysiology and Assessment


Master Eudipharm 2012 Introductory Module, Principles of Discovery of Medicine and Development Planning. Nathan Mewton, MD, PhD. September 26 th 2012

ARRHYTHMIAS AND DEVICE THERAPY

ACUTE ISCHEMIC STROKE. Current Treatment Approaches for Acute Ischemic Stroke

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Practical Considerations in the Early Treatment of Acute Stroke

Case 1 5/26/2017 ENDOVASCULAR MECHANICAL THROMBECTOMY IN PATIENTS WITH ACUTE ISCHEMIC STROKE

COMPREHENSIVE SUMMARY OF INSTOR REPORTS

Starting or Resuming Anticoagulation or Antiplatelet Therapy after ICH: A Neurology Perspective

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging

Left ventricular hypertrophy: why does it happen?

ETIOLOGY AND PATHOGENESIS OF HYPOXIC-ISCHEMIC ENCEPHALOPATHY

Stroke Systems of Care

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

2018 Early Management of Acute Ischemic Stroke Guidelines Update

TABLE OF CONTENTS. MODULE 1: Pathophysiology of Stroke, Neuroanatomy, and Stroke Syndromes. MODULE 2: Acute Stroke Management

Selected age-associated changes in the cardiovascular system

Door to Needle Time: Gold Standard of Stroke Treatment Fatima Milfred, MD. Virginia Mason Medical Center March 16, 2018

Management of new-onset AF: Initial rate control treatment

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Index. Note: Page numbers of article titles are in boldface type.

PREDICTUS - USE OF SYSTEM BIOLOGY TO PREDICT AND DIAGNOSE TRANSITORY ISCHEMIA AND ISCHEMIC TOLERANCE

Chapter 4: Cardiovascular Disease in Patients With CKD

Acute stroke. Ischaemic stroke. Characteristics. Temporal classification. Clinical features. Interpretation of Emergency Head CT

It s Not All One Sided. James Smith, MD (Smitty)

Mitochondrial Implications in Coronary Heart Disease. (Pre-Ischemia)

Choosing Study Outcomes that Reflect Cardiovascular Disease: From Biomarkers to Burden of Disease. Greg Wellenius Joel Kaufman

Redgrave JN, Coutts SB, Schulz UG et al. Systematic review of associations between the presence of acute ischemic lesions on

Hyperuricemia as a Prognostic Marker in Acute Ischemic Stroke

Blood Pressure Management in Acute Stroke. Bradley Molyneaux, M.D., Ph.D. Departments of Neurology & Critical Care Medicine University of Pittsburgh

Asthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload

How to Prevent Thromboembolic Complications in TAVI

: STROKE. other pertinent information such as recent trauma, illicit drug use, pertinent medical history or use of oral contraceptives.

Alan Barber. Professor of Clinical Neurology University of Auckland

SWISS SOCIETY OF NEONATOLOGY. Neonatal cerebral infarction

GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE

Canadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management

High Risk OSA n = 5,359

Prolactin and its cleaved 16-kDa subform. enhance myocardial injury after ischemia/reperfusion

Hypertension The normal radial artery blood pressures in adults are: Systolic arterial pressure: 100 to 140 mmhg. Diastolic arterial pressure: 60 to

Speakers. 2015, American Heart Association 1

Early neurological worsening in acute ischaemic stroke patients

Basilar artery stenosis with bilateral cerebellar strokes on coumadin

Brain Attack. Strategies in the Management of Acute Ischemic Stroke: Neuroscience Clerkship. Case Medical Center

WHAT IS A STROKE? What causes a stroke? What disabilities can result from a stroke?

The DAWN of a New Era for Wake-up Stroke

DISCUSSION QUESTION - 1

Reperfusion Effects After Cardiac Ischemia

TIA SINGOLO E IN CRESCENDO: due diversi scenari della rivascolarizzazione urgente carotidea

Cerebrovascular Disease

Parameter Optimized Treatment for Acute Ischemic Stroke

Advances in Neuro-Endovascular Care for Acute Stroke

Dyslipidemia Endothelial dysfunction Free radicals Immunologic

Stroke Awareness. Presented by: Duane Anderson, MD Snoqualmie Valley Hospital Emergency Department Medical Director

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

HEART AND SOUL STUDY OUTCOME EVENT - MORBIDITY REVIEW FORM

Sex Differences in Stroke Risk and Quality of Life after Stroke

CEREBROVASCULAR DISEASES. By: Shifaa AlQa qa

Philadelphia College of Osteopathic Medicine Annual Progress Report: 2011 Formula Grant

framework for flow Objectives Acute Stroke Treatment Collaterals in Acute Ischemic Stroke framework & basis for flow

Controversies in Risk Stratification

Cardiovascular Disorders Lecture 3 Coronar Artery Diseases

An Introduc+on to Stroke

Stroke is the third-leading cause of death and a major

Cerebral Revascularization For Stroke

Transcription:

Silencing of the Activated Protein-1 Transcription Factor JunD Exacerbates Ischemia/Reperfusion-induced Cerebral Injury Martin F. Reiner, Candela Diaz-Cañestro, Alexander Akhmedov, Heidi Amstalden, Sylvie Briand, Aurora Semerano, Giacomo Giacalone, Stephan Keller, Gerd A. Kullak-Ublick, Maria Sessa, Thomas F. Lüscher, Jürg H. Beer, Giovanni G. Camici Martin F. Reiner, M.D. SSC/SSCS-SSP 216

Background - Stroke Stroke sudden, non-convulsive loss of neurological function due to brain ischemia (8%) or intracranial hemorrhages (2%) Epidemiology 2-25/1 per year Disease burden 4% mortality survivors: 7% reduced work capacity, 3 % assisted self-care Pathophysiology vasculature apoptosis/cell death inflammation reactive oxygen species (ROS) Treatment of ischemic stroke thrombolysis within a time-window of 4.5 h to allow reperfusion of the brain

Background - JunD DNA-binding protein and part of AP-1 transcription factor complex AP-1: dimeric complex mainly of the Jun and Fos subfamilies Jun subfamily: JunD, c-jun, JunB, JunD regulates cell growth, survival and protects against oxidative stress Implication in cardio- and cerebrovascular disease JunD decreases age-induced endothelial dysfunction Lack of JunD promotes cardiac hypertrophy and LV dysfunction

Hypothesis JunD prevents cerebral ischemia/reperfusion injury by decreasing oxidative stress reducing apoptosis and increasin NO biovailability

Vascular JunD responsiveness to cerebral ischemia/reperfusion WT sham ischemia reperfusion WT stroke ischemia reperfusion 45 min 24 hours Transient middle cerebral artery occlusion (tmcao) surgery Middle cerebral artery n=4

Experimental setup: JunD silencing in tmcao ischemia reperfusion sijund ischemia reperfusion 48 hours 45 min 24 hours Stroke Size - 2,3,5-triphenyltetrazolium chloride (TTC) staining Neuromotor Function - Bederson Neurological score - Rotarod - Performance test

in vivo JunD silencing JunD protein expression in murine aortae, 72 hours after sijund injection n = 8/7

Stroke size and neuromotor deficit n = 8/1 Neurological score [-4] 3 2 1 sijund pre-mcao 2 hours 24 hours * post-mcao n = 13/15 RotaRod latency to fall [sec] 1 8 6 4 2 pre-mcao * sijund 24 hours post-mcao n = 13/15

Experimental setup in vitro Human Brain Microvascular Endothelial Cells (HBMVECs) - scramble () vs JunD silencing (sijund) sijund Normoxia (Nx) (8h) Hypoxia (4h)/Reoxygenation (4h) Molecular analysis in HBMVECs JunD responsiveness Cytotoxicity LDH assay Oxidative stress mitochondrial ROS

JunD responsiveness to H/R in HBMVECs n = 6

JunD silencing and cell death in HBMVECs JunD silencing Endothelial cell death 15 LDH release [% of ] 1 5 n = 6 n = 12 sijund

Effects of JunD silencing on cytotoxicity and oxidative stress in HBMVECs exposed to H/R Endothelial cell death Oxidative stress LDH release [% of (H/R)] 15 1 5 * sijund n = 12 Mitochondrial ROS [% of (H/R)] 15 1 5 sijund n = 15

JunD responsiveness to ischemia/reperfusion in peripheral blood monocytes (PBMCs) of stroke patients Study population Controls (n=14) Stroke patients (n=2) p-value Age, years (range) 7.6 (63-82) 74.1 (52-9).275 Female, n (%) 5 (35.7%) 1 (5%).495 Smoking, n (%) (%) 5 (25%).63 Hypertension, n (%) 6 (42.9%) 9 (45%) 1. Dyslipidemia, n (%) 1 (7.1%) 2 (1%) 1. Atrial fibrillation, n (%) (%) 6 (3 %).31 Coronary artery disease, n (%) (%) 4 (2%).126 Previous TIA/stroke, n (%) (%) 2 (1%).51 Peripheral artery disease, n (%) (%) 3 (15%).251 1 8 ** * ns 1 8 ** * ns 1 8 ns ns ns ΔCT (JunD/TBP) [AU] 6 4 ΔCT (JunD/TBP) [AU] 6 4 ΔCT (JunD/TBP) [AU] 6 4 2 2 2 Controls Stroke 6h Stroke 24h Controls Stroke 6h Stroke 24h Controls Stroke 6h Stroke 24h With TPA Without TPA

Summary and Conclusions Ischemia/reperfusion reduces vascular JunD expression in WT mice and in primary HBMVECs Likewise, JunD expression is decreased in PBMs of patients with ischemic stroke undergoing reperfusion therapy Vascular JunD silencing increases stroke size and neuromotor deficit in mice after transient MCAO. JunD silencing increases endothelial cytotoxicity in HBMVECs after hypoxia/reoxygenation. These findings strongly suggests the involvement of JunD in the pathogenesis of ischemia/reperfusion-induced brain damage.

Thank you for your attention!